Tarsons Products' record shows five consecutive unqualified audit opinions, but those opinions mask recurring audit-trail exceptions, repeated working-capital bank-return mismatches, and escalating excess managerial remuneration requiring shareholder waivers each year. The company has also routed over ₹100 crore into a Singapore subsidiary with nil turnover, whose bank loan is backstopped by a ₹96.21 crore parent guarantee, while consolidated profit has declined from ₹42.64 crore in FY24 to ₹29.77 crore in FY25 to ₹14.32 crore in FY26 and ₹11.10 crore in the latest period, and operating cash flow has decoupled from that profitability.
Key findings
- Tarsons has routed over ₹100 crore into its Singapore SPV, which has nil turnover
Major- Tarsons acquired Tarsons Life Science Pte. Ltd. (TLSPL) on 11 November 2023 for 1 USD, then granted it a Euro 12 million loan (₹109.9 crore) in FY2023-24 for the Nerbe acquisition. In FY2024-25, Tarsons provided a ₹96.21 crore standby letter of credit to Citi Bank for TLSPL's loan, which the subsidiary used to repay ₹86.61 crore of the parent's earlier loan, and in FY2025-26 invested ₹31.04 crore in equity that TLSPL used to repay another ₹21.84 crore parent loan. TLSPL reported turnover of ₹17.81 crore for FY2024-25 and nil turnover for FY2025-26, with a ₹109.30 crore loss and negative reserves of ₹175.25 crore for FY2024-25, while the Nerbe step-downs contributed ₹80 crore revenue but a ₹10.68 crore consolidated loss. - Five unqualified opinions include recurring audit-trail and bank-return exceptions
Major- Price Waterhouse issued unqualified opinions for FY2021-22 through FY2025-26, but the Section 143(3)(b) opinion for FY2025-26 is qualified by an audit-trail exception: the edit-log feature was not maintained for certain records modified by certain users and not enabled for direct database changes, the same exception reported in FY2024-25 and FY2023-24. CARO clause 3(ii)(b) reports working-capital bank returns not in agreement with books for FY2024-25 (₹5.59 crore and ₹1.35 crore differences) and FY2022-23, with no returns filed for quarters ended March 31, 2025 and March 31, 2026. Excess managerial remuneration requiring shareholder approval grew from ₹0.36 crore in FY2023-24 to ₹1.38 crore in FY2024-25 to ₹4.14 crore in FY2025-26. - Reported borrowings understate economic obligations through reclassification and guarantees
Major- Supplier finance arrangements with A. Treds and Mynd Solutions reclassify trade payables to borrowings, with cash outflows presented in financing rather than operating activities. A Euro 10.6 million (₹96.21 crore) Citi Bank loan to TLSPL is backstopped by a parent corporate guarantee, secured by first pari passu charges over the group's inventories and receivables plus an exclusive mortgage on land and buildings at Amta. Working capital facilities from seven banks are secured by pari passu first hypothecation over substantially all current assets, with gearing rising from 0.20x in FY23 to 0.53x in FY24 and credit ratings downgraded from 'CARE A+/A1+' to 'CARE A/A1' in FY2026. - Promoter executive directors exceeded remuneration limits in each of the last three years
Major- Excess managerial remuneration requiring shareholder waiver grew from ₹0.36 crore in FY2023-24 to ₹1.38 crore in FY2024-25 to ₹4.14 crore in FY2025-26, with the FY2025-26 excess split between Managing Director Sanjive Sehgal (₹1.97 crore), Whole-Time Director Aryan Sehgal (₹2.05 crore), and other directors (₹0.12 crore). A remuneration revision effective 1 September 2025 reduced Sanjive Sehgal's pay from ₹4.25 crore to ₹3.75 crore and increased Aryan Sehgal's from ₹3.75 crore to ₹4.25 crore, described as a voluntary transition to next-generation leadership. Two independent directors resigned before term expiry in FY2025-26, and median employee remuneration decreased 12.28% in FY2025-26. - Recurring contingent exposures from customs, GST, land-use, and EPCG obligations
Minor- A 22 August 2025 customs order demands ₹4,50,835 plus interest, penalty, and a ₹7,00,000 redemption fine, which the Company intends to appeal. A 16 November 2023 CGST order demands ₹66,14,409 plus interest and ₹6,61,441 penalty for incorrect transitional credit claims, with the Company contemplating appeal. The factory land at Jangalpur has not received complete approval for non-agricultural use under the West Bengal Land Reforms Act, disclosed in every annual report from FY2021-22 through FY2025-26, and EPCG obligations require exports of six times duty saved over six years. The EUR 15 million Nerbe earn-out guarantee was revoked in FY2024-25 after the seller confirmed non-fulfilment of the FY2024 EBITDA criteria. - Revenue recognition is routine, but receivables quality is deteriorating
Minor- Revenue is recognised at a point in time when control transfers, with no customer exceeding 10% of outstanding receivables in any of the last three years. Allowance for expected credit losses on trade receivables increased 44% to ₹6.29 crore as at 31 March 2025 from ₹4.37 crore a year earlier, with a ₹1.90 crore provision made during FY25. Revenue declined from ₹423 crore in FY26 to ₹392 crore in FY25 to ₹296 crore in FY24, while receivable days improved from 95.91 in FY24 to 73.77 in FY26, and management warned a future quarter could be bad due to shipment timing.
What to watch
- Shareholder vote on ₹4.14 crore excess remuneration waiver. The special resolution to waive recovery of FY2025-26 excess managerial remuneration will be voted on at the ensuing AGM, as proposed in the FY2025-26 Annual Report.
- Quarterly equity infusions into TLSPL. Completion of quarterly tranches on or before 31 March 2027, as announced on 6 February 2026, will determine whether the subsidiary can repay its Citi Bank loan.
- Settlement of the Euro 10.6 million Citi Bank loan. Default by TLSPL would trigger the parent's standby letter of credit and pledged assets, as disclosed in the FY2025-26 Annual Report.
- Filing of the March 31, 2026 working capital returns. These were not yet filed as of the FY2025-26 reporting date, and prior-year filings showed material differences from books.
- Receipt of the 0.56 crore overdue interest from TLSPL. This payment was due 31 March 2025 and remained unpaid as of the FY2024-25 reporting date.
- Nerbe CGU impairment test as at 31 March 2027. The 15% sales growth assumption used in prior tests will be tested against declining consolidated profitability in the FY2026-27 annual report.
- Outcome of customs and GST appeals. The Company's intended appeal against the 22 August 2025 customs order and contemplated appeal against the 16 November 2023 CGST order remain unresolved.
Bottom line: This is a disclosed and audited record with real cash generation, but the cash is decoupling from profit, the Singapore subsidiary is a growing liability with no revenue, and the auditor's clean opinions carry recurring exceptions. The risk sits in the subsidiary structure, the debt-funded capex, and the promoter pay that keeps exceeding legal limits. Watch the shareholder vote, the Citi Bank loan, and the next impairment test.